132 related articles for article (PubMed ID: 12799209)
1. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
[TBL] [Abstract][Full Text] [Related]
2. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
[TBL] [Abstract][Full Text] [Related]
3. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
[TBL] [Abstract][Full Text] [Related]
4. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
[TBL] [Abstract][Full Text] [Related]
5. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
[TBL] [Abstract][Full Text] [Related]
6. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
[TBL] [Abstract][Full Text] [Related]
7. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
[TBL] [Abstract][Full Text] [Related]
8. Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre L; Walley KR
Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
[No Abstract] [Full Text] [Related]
9. USAN Council. List No.407. New names. Lenercept.
Clin Pharmacol Ther; 1998 Aug; 64(2):234. PubMed ID: 9758530
[No Abstract] [Full Text] [Related]
10. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
[TBL] [Abstract][Full Text] [Related]
12. Animal pharmacokinetics of the tumor necrosis factor receptor-immunoglobulin fusion protein lenercept and their extrapolation to humans.
Richter WF; Gallati H; Schiller CD
Drug Metab Dispos; 1999 Jan; 27(1):21-5. PubMed ID: 9884305
[TBL] [Abstract][Full Text] [Related]
13. Effects of nitroglycerin on sublingual microcirculatory blood flow in patients with severe sepsis/septic shock after a strict resuscitation protocol: a double-blind randomized placebo controlled trial.
Boerma EC; Koopmans M; Konijn A; Kaiferova K; Bakker AJ; van Roon EN; Buter H; Bruins N; Egbers PH; Gerritsen RT; Koetsier PM; Kingma WP; Kuiper MA; Ince C
Crit Care Med; 2010 Jan; 38(1):93-100. PubMed ID: 19730258
[TBL] [Abstract][Full Text] [Related]
14. Plasma cytokine measurements augment prognostic scores as indicators of outcome in patients with severe sepsis.
Oberholzer A; Souza SM; Tschoeke SK; Oberholzer C; Abouhamze A; Pribble JP; Moldawer LL
Shock; 2005 Jun; 23(6):488-93. PubMed ID: 15897799
[TBL] [Abstract][Full Text] [Related]
15. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
Harbarth S; Garbino J; Pugin J; Romand JA; Lew D; Pittet D
Am J Med; 2003 Nov; 115(7):529-35. PubMed ID: 14599631
[TBL] [Abstract][Full Text] [Related]
16. A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock.
Aikawa N; Takahashi T; Fujimi S; Yokoyama T; Yoshihara K; Ikeda T; Sadamitsu D; Momozawa M; Maruyama T
J Infect Chemother; 2013 Oct; 19(5):931-40. PubMed ID: 23681364
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the efficacy and safety of two doses of the polyclonal anti-tumor necrosis factor-α fragment antibody AZD9773 in adult patients with severe sepsis and/or septic shock: randomized, double-blind, placebo-controlled phase IIb study*.
Bernard GR; Francois B; Mira JP; Vincent JL; Dellinger RP; Russell JA; Larosa SP; Laterre PF; Levy MM; Dankner W; Schmitt N; Lindemann J; Wittebole X
Crit Care Med; 2014 Mar; 42(3):504-11. PubMed ID: 24335445
[TBL] [Abstract][Full Text] [Related]
18. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of affinity-purified, anti-tumor necrosis factor-alpha, ovine fab for injection (CytoFab) in severe sepsis.
Rice TW; Wheeler AP; Morris PE; Paz HL; Russell JA; Edens TR; Bernard GR
Crit Care Med; 2006 Sep; 34(9):2271-81. PubMed ID: 16810105
[TBL] [Abstract][Full Text] [Related]
20. Soluble TNFR II/IgG1 Fc fusion protein treatment in the LPS-mediated septic shock of rats.
Guo Z; Wang S; Jiao Q; Xu M; Xu Z
Biomed Pharmacother; 2009 Aug; 63(7):537-42. PubMed ID: 18848768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
